the Journal of Studies on Alcohol and Drugs
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Adults should have no more than one drink a day, a team of scientists says
Americans should limit their alcohol consumption to no more than one drink per day, according to a study published Tuesday in the Journal of Studies on Alcohol and Drugs. The recommendation — from an international team of scientists — differs from the U.S. dietary guidelines, both past and present. Previous guidelines recommended a daily limit of two alcoholic drinks for men and one for women.
Disability, disease and death warning for anyone drinking alcohol
Disability, disease and death warning for anyone drinking alcohol A major new study has prompted an urgent 'danger' alert One glass of wine or pint of beer a day is enough to increase the risk of cancer and heart disease, warns new research. Even what most people consider a "moderate" or sensible level of alcohol intake "substantially" elevates the dangers of dying young, disability and chronic diseases, say scientists.
Study that was sidelined by Trump administration tells Americans to limit themselves to one drink per day
Study that was sidelined by Trump administration tells Americans to limit themselves to one drink per day Researchers commissioned by President Joe Biden's Democratic administration to investigate alcohol-related health harms have released their findings independently - Bookmark A significant study commissioned by the administration of President Joe Biden, investigating alcohol-related health harms, was independently released on Tuesday, after the administration of Donald Trump reportedly...
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
Abstract Nuclear receptors are central regulators of metabolism1, yet therapeutic strategies that enforce continuous receptor activation frequently lead to reduced efficacy and unacceptable toxicity. Here we report a first-principles drug design strategy that aligns pharmacokinetics with physiological signalling cycles. We developed linafexor, a potent non-bile-acid agonist of the farnesoid X receptor (FXR)2; it is engineered for rapid systemic clearance, which enables pulsatile receptor...